Primary Objective: Part 1 - To evaluate the safety and tolerability of cobolimab in combination with dostarlimab in pediatric and young adult participants with advanced solid tumors. - To evaluate the PK profile of cobolimab in combination with dostarlimab in pediatric and young adult participants with advanced solid tumors. - To determine the RP2D of cobolimab in combination with dostarlimab in pediatric and young adult participants with advanced solid tumors Part 2 -To evaluate the anti-tumor activity of cobolimab in combination with dostarlimab in pediatric and young adult participants with melanoma (Cohort A), Hodgkin lymphoma (Cohort B), and selected pathologies (Cohort C+) in pediatric and young adult participants with advanced solid tumors -To evaluate the safety and tolerability of cobolimab in combination with dostarlimab in pediatric and young adult participants with melanoma (Cohort A) Hodgkin lymphoma (Cohort B), and selected pathologies (Cohort C+) in pediatric and young adult participants with advanced solid tumors Secondary Objectives: Part 1 - To evaluate target engagement (pharmacodynamics) of cobolimab in combination with dostarlimab - To evaluate the measures of clinical benefit of cobolimab in combination with dostarlimab - To evaluate Immunogenicity (ADA) of cobolimab and dostarlimab in pediatric and young adult participants with advanced solid tumors Part 2 -To evaluate additional measures of clinical benefit for cobolimab in combination with dostarlimab in pediatric and young adult participants with melanoma, Hodgkin lymphoma, and other selected pathologies -To evaluate the PK profile of cobolimab in combination with dostarlimab -To evaluate pharmacodynamics of cobolimab in combination with dostarlimab -To evaluate Immunogenicity (ADA) of cobolimab and dostarlimab
What is the full name of this clinical trial?
219451: Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors